Anzeige
Mehr »
Freitag, 24.10.2025 - Börsentäglich über 12.000 News
Gold über 4.000 US-Dollar - Canary Gold startet Multi-Front-Exploration in Brasiliens neuem Gold-Hotspot
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
29.09.BioLineRx forges partnership with Norwegian biotech to advance cancer candidate
29.09.After surprise trial listing, Applied Tx still doesn't have any updates on its rare disease asset
29.09.Gilead pumps up virology pipeline with drug transporter deal
29.09.IO lays off 50% of employees after FDA derails cancer vaccine approval plan
29.09.Enanta sees RSV drug fail phase 2b but finds positives in secondaries and subgroup
29.09.MoonLake's stock crashes after high placebo rate eclipses IL-17 drug's phase 3 readouts
29.09.Genmab pays $8B to buy Merus and its phase 3 bispecific that wowed analysts
26.09.Biogen officially ends all AAV gene therapy work, prompting team restructure
26.09.New nine-figure ARPA-H programs seek to deliver custom gene editing treatments to more patients
26.09.Eli Lilly opens incubator site in San Diego, with 'several' biotechs already on board
26.09.Fierce Biotech's Fierce 15
26.09.US biotechs think twice about EU licensing deals amid Trump's drug pricing campaign
25.09.NIH earmarks $87M for new organoid center as pivot away from animal testing continues
25.09.Eli Lilly withdraws phase 2b trial of $1.9B obesity bet before starting enrollment
25.09.Heidelberg to lay off 75% of staff after milestone becomes millstone
24.09.Average biopharma biobucks decline, while upfront deal payments rise: SRS Acquiom
24.09.Sparrow flies forward with $95M series B for midstage diabetes asset
24.09.Harmony's pivotal Fragile X trial flops as high placebo response creates discord
24.09.uniQure hopes to launch 1st Huntington's gene therapy next year following phase 1/2 success
24.09.Cyclerion cycles through latest pivot, reinventing itself as neuro biotech
23.09.Big Pharma-backed Rome Therapeutics nears end of road with planned layoffs and strategic review
23.09.Wall Street spotlight: NYSE honors this year's Fierce 15 winners
23.09.Seres shrinks head count by 25% to fund phase 2 study of infection biotherapeutic
23.09.Bristol Myers midtrial endpoint addition secures phase 3 win in multiple myeloma
23.09.Roche's 'top three' obesity ambition not reliant on developing one megablockbuster